Day One Biopharmaceuticals (Day One Biopharmaceuticals) Inventory Turnover : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Day One Biopharmaceuticals's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Day One Biopharmaceuticals's Average Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Day One Biopharmaceuticals Inventory Turnover Historical Data

The historical data trend for Day One Biopharmaceuticals's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals Inventory Turnover Chart

Day One Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory Turnover

Day One Biopharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventory Turnover	Get a 7-Day Free Trial													-	-	-	-	-

Day One Biopharmaceuticals Inventory Turnover Calculation

Day One Biopharmaceuticals's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory Turnover (A: Dec. 2023 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2023 )	/ (	(Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Day One Biopharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

	Inventory Turnover (Q: Mar. 2024 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Mar. 2024 )	/ (	(Total Inventories (Q: Dec. 2023 )	+	Total Inventories (Q: Mar. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Day One Biopharmaceuticals (NAS:DAWN) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Day One Biopharmaceuticals's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2024 )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Day One Biopharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	0
	=

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Day One Biopharmaceuticals Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005

Website

https://www.dayonebio.com

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Executives

York Charles N Ii	officer: COO, CFO and Secretary	901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Samuel C. Blackman	officer: Chief Medical Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Jeremy Bender	director, officer: Chief Executive Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Ai Day 1 Llc	10 percent owner	40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant	director	2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p.	10 percent owner	2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone	director	395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc.	10 percent owner	ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc.	10 percent owner	9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John A. Josey	director	C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235